2025 Endocrinology Grand Rounds | Management of Neuroendocrine Tumors from an Endocrinologist's Perspective
Neuroendocrine tumors are rare and have an indolent clincial course. Inadequate theoretical knowledge and clinical experience among endocrinologists for early diagnosis, as well as insufficient exposure to patient endocrine manifestation of neuroendocrine tumor leads to current state. This, coupled with the fact that many endocrine programs do not have an adequate curriculum for how to diagnose and treat neuroendocrine tumors is concerning.
There is an increasing incidence of neuroendocrine tumors, yet regrettably, there is limited updated epidemiologic data, which results in insufficient knowledge of these tumors. Therefore, it is necessary to provide a platform to discuss the diagnostic approach for neuroendocrine tumors, as well as the managemenet of endocrine manifestation in neuroendocrine tumors.
Target Audience
Faculty and staff of the Department of Diabetes, Endocrinology and Metabolism, and all other allied healthcare providers interested in the subject matter.
Learning Objectives
- Outline the epidemiology of neuroendocrine tumors.
- Discuss clinical manifestation of hormone secreting neuroendocrine tumor.
- Integrate laboratory and imaging modalities in diagnosis of neuroendocrine tumors.
- Outline hormonal management of neuroendocrine tumors.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Behrouz Salehian, MD Clinical Professor, Department of Diabetes, Endocrinology and Metabolism, City of Hope
Presenter: Dr. Salehian has indicated that there are no relevant financial relationships with ineligible companies.
Planner: Pooja Manroa, MD has indicated that there are no relevant financial relationships with ineligible companies.
This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2025 Endocrinology Grand Rounds | Management of Neuroendocrine Tumors from an Endocrinologist's Perspective for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance